Preliminary evidence indicates that the amount in milk is very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[1] Many infants have been breastfed during maternal omalizumab therapy, with no increase in infectious complications. Omalizumab is considered acceptable to use during breastfeeding.[2,3] Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[4]